心臓チャネロパシーにおける性別の違い:臨床実務への影響
Babken Asatryan1, Lauren Yee2, Yael Ben-Haim3,4
1Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland (B.A., S.D., H.S., L.R., H.T., T.R., K.E.O.).
Circulation
|February 15, 2021
まとめ
性別はQT延長症候群やブルガダ症候群のような心臓のチャネル病に 影響を及ぼし,男性と女性の疾患リスクと結果が異なる. 性別による差異を理解することは パーソナライズされた患者のケアに不可欠です
科学分野:
- 心臓病科
- 遺伝学
- 内分泌学
背景:
- 心臓チャネル病は,遺伝的傾向が同じであるにもかかわらず,流行,発現,および結果において性に関連した違いを示します.
- 生まれつきのQT延長症候群やブルガダ症候群のような疾患では 性別別別別の不律症や 突然心不全の危険性があります
- これらの差異は,心臓のイオンチャネルを調節する年齢と性ホルモンの影響を受けます.
研究 の 目的:
- 心臓チャネル病の性差に関する現在の証拠をレビューする.
- 臨床的影響を強調し,知識のギャップを特定する.
- 性別特定の研究と報告の必要性を強調する.
主な方法:
- 心臓チャネル病の性差に関する研究の文献レビュー.
- 臨床データと実験結果の分析
- 遺伝的,ホルモン的,環境的要因に関する証拠の合成
主要な成果:
- 成人女性は先天性QT延長症候群のリスクが高く,成人の男性はブルガダ症候群に優勢です.
- いくつかのチャネル病変において,性特異的な結果の予測要因が特定されています.
- 性ホルモンは心臓のイオンチャネル機能に影響を与えることで不平等に作用します.
結論:
- 性別特異的な要因は,心臓チャネル病のリスクと結果に大きな影響を及ぼします.
- これらの違いの背後にあるメカニズムを理解するためにさらなる研究が必要です.
- 性別に関するパラメータの報告は不可欠です.
さらに関連する動画
関連する概念動画
Cardiomyopathy III: Hypertrophic Cardiomyopathy
146
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
146
Electrophysiology of Normal Cardiac Rhythm
8.1K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
8.1K
Mechanism of Cardiac Arrhythmias
1.4K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.2K
Pathophysiology of Cardiac Performance
1.1K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.1K
Dysrhythmias VI: Management of Dysrhythmias
223
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
223


